- August 2, 2022
- Newsletter
- 617-430-5616
Menu
Brand Name :
Trandate
Synonyms :
labetalol
Class :
Antihypertensive and alpha/beta-blockers
Dosage Forms & Strengths
Injectable solution
5mg/ml
Tablet
100mg
200mg
300mg
100
mg
Orally
every 12 hrs
initially; increased up to100 mg for 12hrs every 2-3 days Usual dosage range: 200-400 mg orally every 12hrs Do not exceed 2400 mg per day
20
mg
Intravenous (IV)
over 2 minutes initially
then 40-80 mg IV for every 10min
Do not exceed 300 mg per day
Dosage Forms & Strengths
Injectable solution
5mg/ml
Tablet
100mg
200mg
300mg
0.4 - 1
mg/kg
per hour by continuous IV infusion
do not exceed 3 mg/kg per hour
13
mg/kg
Orally
once a day
or divided for every 12hr
do not exceed 1200 mg per day
bradycardia-Causing Agents may enhance the bradycardic effect of Ceritinib
bradycardia-Causing Agents may enhance the bradycardic effect of ponesimod
may increase the bradycardic effect of bradycardia-causing agents
may have an increased bradycardic effect when combined with fingolimod
may have an increased bradycardic effect when combined with ponesimod
may have an increased bradycardic effect when combined with siponimod
may decrease the diagnostic effect when combined with benzylpenicilloyl polylysine
may have an increased hypertensive effect when combined with alpha1-blockers
may increase the risk of adverse effects
may increase the risk of adverse effects
may increase the risk of adverse effects
may increase the risk of adverse effects
may increase the risk of adverse effects
may enhance the hypotensive effect of phosphodiesterase 5 Inhibitors
may increase the vasoconstricting effect of Ergot Derivatives
may increase the hypotensive effect of alpha1-blockers
may increase the hypotensive effect of alpha1-blockers
may increase the hypotensive effect of alpha1-blockers
may increase the hypotensive effect of alpha1-blockers
may increase the hypotensive effect of alpha1-blockers
may decrease the bronchodilatory effect of beta2-agonists
may decrease the bronchodilatory effect of beta2-agonists
may decrease the bronchodilatory effect of beta2-agonists
may decrease the bronchodilatory effect of beta2-agonists
may decrease the bronchodilatory effect of beta2-agonists
may have an increased hypotensive effect when combined with calcium channel blockers
may have an increased hypotensive effect when combined with calcium channel blockers
may have an increased hypotensive effect when combined with calcium channel blockers
may have an increased hypotensive effect when combined with calcium channel blockers
may have an increased hypotensive effect when combined with calcium channel blockers
may decrease the bronchodilatory effect when combined with beta2-agonists
may decrease the bronchodilatory effect when combined with beta2-agonists
may decrease the bronchodilatory effect when combined with beta2-agonists
bradycardia causing agents increase the arrhythmia-causing effect of fexinidazole
may decrease the bronchodilatory effect
may increase the hypertensive effect of Monoamine Oxidase inhibitors
may increase the hypertensive effect of Monoamine Oxidase inhibitors
may decrease the bronchodilatory effect of each other when combined
may decrease the vasoconstriction effects
may enhance the effect of other bradycardia agents
may enhance the effect of other bradycardia agents
may enhance the effect of other bradycardia agents
may enhance the effect of other bradycardia agents
may enhance the effect of other bradycardia agents
may decrease the vasoconstricting effect when combined with alpha1-agonists
may enhance the hypoglycemic effect
may enhance the hypoglycemic effect
may enhance the hypoglycemic effect
may enhance the hypoglycemic effect
may enhance the hypoglycemic effect
may increase the vasoconstricting effect
may increase the vasoconstricting effect
may increase the vasoconstricting effect
may increase the vasoconstricting effect
may increase the vasoconstricting effect
may reduce the vasoconstriction-inducing action
may decrease the vasoconstricting effect when combined with alpha1-agonists
bunazosin (Not available in the United States)
may decrease the vasoconstricting effect when combined with alpha1-agonists
may decrease the vasoconstricting effect when combined with alpha1-agonists
may decrease the vasoconstricting effect when combined with alpha1-agonists
may decrease the vasoconstricting effect when combined with alpha1-agonists
may decrease the constriction effects of alpha-1 agonist
may decrease the constriction effects of alpha-1 agonist
hydrocodone/chlorpheniramine/pseudoephedrine
may decrease the vasoconstriction effects of alpha/beta agonists
may increase the bradycardia effect
may enhance the effect of other bradycardia agents
may enhance the effect of other bradycardia agents
may enhance the effect of other bradycardia agents
may enhance the effect of other bradycardia agents
may enhance the effect of other bradycardia agents
bradycardia-causing agents increase the efficacy of ivabradine
may increase the hypotensive effect
may enhance the hypotensive effect of Alpha1-Blockers
may enhance the hypotensive effect of Alpha1-Blockers
may enhance the hypotensive effect of Alpha1-Blockers
may enhance the hypotensive effect of Alpha1-Blockers
may enhance the hypotensive effect of Alpha1-Blockers
may decrease the bronchodilatory effect of beta-blockers
may decrease the bronchodilatory effect of beta-blockers
may decrease the bronchodilatory effect of beta-blockers
may decrease the bronchodilatory effect of beta-blockers
may decrease the bronchodilatory effect of beta-blockers
acrivastine and pseudoephedrine
may increase the vasoconstrictive effect of alpha/beta agonists
may increase the bradycardic effect of bradycardia-causing agents
may increase the hypotensive effect of calcium channel blockers
may increase the hypotensive effect of calcium channel blockers
may enhance the orthostatic effect of beta blockers
may enhance the bradycardic effect of bradycardia-causing agents
may increase the effect of alpha1-blockers
may increase the effect of alpha1-blockers
may increase the effect of alpha1-blockers
may increase the effect of alpha1-blockers
may increase the effect of alpha1-blockers
may increase the effect of alpha1-blockers
may increase the hypotensive effect of blood pressure lowering agents
may decrease the antihypertensive effect when combined with beta-blockers
may decrease the antihypertensive effect when combined with beta-blockers
may decrease the antihypertensive effect when combined with beta-blockers
may decrease the antihypertensive effect when combined with beta-blockers
may decrease the antihypertensive effect when combined with beta-blockers
may decrease the vasoconstricting effect when combined with alpha-/beta-agonists
may decrease the vasoconstricting effect of Alpha-/Beta-Agonists
alkalinizing agents: they may enhance the serum concentration of Alpha or Beta-Agonists
alkalinizing agents: they may enhance the serum concentration of Alpha or Beta-Agonists
alkalinizing agents: they may enhance the serum concentration of Alpha or Beta-Agonists
alkalinizing agents: they may enhance the serum concentration of Alpha or Beta-Agonists
alkalinizing agents: they may enhance the serum concentration of Alpha or Beta-Agonists
may increase the bradycardic effect of each other
may increase the effects of bosentan by pharmacodynamic synergism
midodrine: they may increase the bradycardic effect of Bradycardia-Causing Agents
ozanimod: they may increase the bradycardic effect of Bradycardia-Causing Agents
tofacitinib: they may increase the bradycardic effect of Bradycardia-Causing Agents
it may diminish the excretion rate when combined with Growth hormone agonist, resulting in an enhanced serum level
it may diminish the excretion rate when combined with Growth hormone agonist, resulting in an enhanced serum level